HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Cardiology28534 papers

Diabetes mellitus

Last edited: 4/23/2026

Overview

Diabetes mellitus encompasses type 1 and type 2 diabetes, characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both, leading to significant microvascular and macrovascular complications 1.

Diagnosis

Key Diagnostic Criteria: Elevated fasting plasma glucose, HbA1c ≥6.5%, or glucose tolerance test results 1.

Recommended Tests: HbA1c, fasting plasma glucose, oral glucose tolerance test 1.

Grading: HbA1c ≥6.5% confirms diagnosis without confirmatory testing; other tests require confirmatory testing 1.

Management

First-Line Treatments:

- Type 1 Diabetes: Insulin therapy (basal-bolus regimen) 1. - Type 2 Diabetes: Lifestyle modifications (diet, exercise), metformin 1.

Adjunctive Treatments:

- GLP-1 Receptor Agonists: For glycemic control and cardiovascular benefits (e.g., liraglutide, semaglutide) 1 33 68. - SGLT2 Inhibitors: For glycemic control and cardiovascular risk reduction (e.g., empagliflozin, canagliflozin) 1 21. - DPP4 Inhibitors: For glycemic control (e.g., sitagliptin, linagliptin) 1 17.

Lipid Management: Statin therapy to manage cardiovascular risk 1 29 30.

Special Populations

Pregnancy: Close monitoring of blood glucose, insulin therapy often required 1.

Elderly: Focus on polypharmacy management and cardiovascular risk reduction 10 11 12.

Comorbidities: Tailored management considering comorbidities like cardiovascular disease, renal impairment, and retinopathy 1 3 15 25 35.

Key Recommendations

Optimize Glycemic Control: Aim for individualized HbA1c targets, considering patient-specific factors (Evidence: Strong 1 39).

Cardiovascular Risk Management: Include SGLT2 inhibitors or GLP-1 receptor agonists in patients at high cardiovascular risk (Evidence: Strong 1 21 33).

Regular Monitoring: Frequent monitoring of HbA1c, blood pressure, and lipid profiles to prevent complications (Evidence: Moderate 1 60).

Lifestyle Interventions: Encourage lifestyle modifications including diet and physical activity for all patients (Evidence: Moderate 1 46).

Screening for Complications: Regular screening for retinopathy, nephropathy, and neuropathy, especially in high-risk groups (Evidence: Moderate 1 3 5).

Polypharmacy Awareness: Monitor and manage polypharmacy to avoid inappropriate prescribing in older adults (Evidence: Moderate 10 11).

References

Showing 100 most recent of 12697 indexed papers.

1 . 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes care 2026. link 2 Nopour R. Barriers and facilitators to the use of tele-ophthalmology in diabetic eye care: a scoping review. BMC health services research 2026. link 3 Tang Y, Li Z, Jia Z. Systematic review of ocular and circulatory cytokines linking diabetic retinopathy to kidney disease. Frontiers in endocrinology 2026. link 4 Rosenberg K. AI-led intervention may be viable option for diabetes prevention. The American journal of nursing 2026. link 5 Cook CB, Thompson BM, Perrin AJ, Castro JC, McGary AK, Buras MR. Assessing the Complexity of Inpatient Care Managed by Endocrinologists in a Tertiary Care Teaching Hospital. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026. link 6 Wang Y, Zhang CL, Zhao H, Wang C, Guo L, Wei P et al.. Efficacy of ChatGPT in personalized glucose-lowering strategy development: a clinician-based comparative study. Frontiers in endocrinology 2026. link 7 Sng GGR, Lim GH, Tian KJY, Bee YM, Teh MM. Trends in admissions for hyperglycaemic emergencies and associated clinical factors in adults with type 2 diabetes in Singapore, 2013-2022. Diabetic medicine : a journal of the British Diabetic Association 2026. link 8 Alotaibi AO, Bakitian F, Alshammari HD, Alqhtani A, Elboraey MO, Fayad MI et al.. Associations Between Comorbidities, Medication Use and Dental Outcomes in Clinical Practice in Hail Dental Centre in Saudi Arabia: A Retrospective Study. Oral health & preventive dentistry 2026. link 9 Kubo H, Sozu T, Mitsunaga R, Hazama H, Sekikawa N, Wada R et al.. Experienced stigma in Japanese outpatients with diabetes: Age and polypharmacy matter. Medicine 2026. link 10 Ali N, van Erp S, Kramers C, Tack CJ, de Galan BE. The Prevalence and Implications of Polypharmacy in Individuals With Type 1 Diabetes. Clinical pharmacology and therapeutics 2026. link 11 Berthon W, McGurnaghan SJ, Blackbourn LAK, Fernandes AAS, Walker LE, McCrimmon RJ et al.. Polypharmacy and potentially inappropriate prescribing in people with type 2 diabetes: An analysis of the Scottish Diabetes Research Network national diabetes cohort. Diabetic medicine : a journal of the British Diabetic Association 2026. link 12 Zomer E, Morton JI, Chen L, Talic S, McAuley SA, Davis EA et al.. Medication Use in Type 1 Diabetes and the Association with Socioeconomic Disadvantage: Analysis of a National Linked Dataset. Diabetes technology & therapeutics 2026. link 13 Meng K, Fu S, Huang Y, Chen W, Zou W. Fulminant type 1 diabetes mellitus: a neglected but high-risk adverse event associated with immune checkpoint inhibitors. Expert opinion on drug safety 2026. link 14 Li Z, Huang J, Zhou S, Luan Y, Xie H, Chen Z et al.. Safety Assessment of Glucagon-Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations. Journal of diabetes research 2026. link 15 Ohyama K, Abe N, Okamoto T, Hori Y. Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System. International journal of clinical pharmacology and therapeutics 2026. link 16 McIntyre RS, Kwan ATH. Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study. Expert opinion on drug safety 2026. link 17 Xiong W, Li Y, Huang J, He G, Sun J. Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS). PloS one 2026. link 18 Murray M, Schifano F, Chiappini S, Corkery JM, Guirguis A. Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database. American journal of ophthalmology 2026. link 19 Zhong L, Cao W, Liu X, Wen T, Yan J. A FAERS database study on visual impairment adverse events associated with three long-acting insulin analogues. Frontiers in endocrinology 2026. link 20 Cheng X, Jiang Z, Li G, Wang J, Han F. Multi-database pharmacovigilance assessment of GLP-1 receptor agonist-related ophthalmic risks using advanced signal detection in FAERS and vigibase. Journal of endocrinological investigation 2026. link 21 Ahsan M. Serious adverse events reported with sodium-glucose cotransporter-2 (SGLT2) inhibitors in the FAERS database (2013-2024): a pharmacovigilance study. Naunyn-Schmiedeberg's archives of pharmacology 2026. link 22 Deng B, Li S, You R, Fu Z. Diabetic adverse events associated with three commonly used statins: a disproportionality analysis based on the FDA adverse event reporting system database. Expert opinion on drug safety 2026. link 23 Fat MN, Johnson HC, Farberg AS. Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024. Journal of drugs in dermatology : JDD 2026. link 24 McCall KL, Mastro Dwyer KA, Casey RT, Samana TN, Sulicz EK, Tso SY et al.. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert opinion on drug safety 2026. link 25 Kong WM, Saif F. Can artificial intelligence and wearable technologies transform diabetes foot health?. Current opinion in endocrinology, diabetes, and obesity 2026. link 26 Benedetti A, Bringmans T, Vanhaverbeke M, Mathieu FD, Palmers PJ, Coussement P et al.. Invasive coronary physiology assessment and predictors of coronary microvascular dysfunction in patients with diabetes mellitus. Microvascular research 2026. link 27 Sumawe JA, Salingwa L. Doppler sonographic evaluation of peripheral arterial disease and its associated factors among diabetes mellitus patients at Muhimbili National Hospital, Tanzania: A hospital-based cross-sectional study. PloS one 2026. link 28 Zuo C, Chen H, Lu X, Cheng J, Yang D, Liu Y et al.. VEGFA-centric angiogenic genetic variants drive hypertension and dyslipidaemia susceptibility in type 2 diabetes mellitus: A multilocus synergistic cohort study. Diabetic medicine : a journal of the British Diabetic Association 2026. link 29 Bui L, Le TT, Dao NH, Nguyen HT, Nguyen TT, Pham VTT et al.. Statin prescribing patterns in cardiovascular risk management among outpatients with type 2 diabetes: Real-world practices at a Vietnamese general hospital. PloS one 2026. link 30 Wang B, Tse ETY, Chui CSL, Lam CLK, Wan EYF. Optimising lipid monitoring interval for primary prevention of cardiovascular disease in patients with type-2 diabetes: A target trial emulation study. Diabetes research and clinical practice 2026. link 31 Huang Y, Liu Y, Wang Y, Liu X, Ji S, Chen S et al.. Age- and diet-dependent progression of retinal microvascular injury in GCK-MODY under metabolic stress. Frontiers in endocrinology 2026. link 32 Iwasaki Y, Shimada T, Kishimori T, Kato T, Koike J, Matsumoto T et al.. Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin. Diabetes research and clinical practice 2026. link 33 Firdoos S, Dai R, Shah FA, Younas Z. Attenuation of Vascular Dementia Associated Neuroinflammation by Inhibition of the JNK Pathway in HFD/STZ-Induced Diabetic Rat Model. Clinical and experimental pharmacology & physiology 2026. link 34 Chen P, Ahluwalia R, Chuo CB, Johnson-Lynn SE. Management of the acute diabetic foot : an update. The bone & joint journal 2026. link 35 Frampton R, Hocking S, Snaith JR, Greenfield JR. Targeting cardiometabolic risk in type 1 diabetes through incretin physiology. Trends in endocrinology and metabolism: TEM 2026. link 36 Tsukatani T, Nakada A. Association of routine clinical indicators for metabolic and cardiovascular health with weight loss in non-obese older adults: A case-control study using annual health screening data in Japan. Geriatric nursing (New York, N.Y.) 2026. link 37 Li N, Sun J, Li H, Li C, Wang X, Ji J et al.. Drug-gene interactions and the risk of diabetic microvascular complications: A population-based cohort study. Diabetes, obesity & metabolism 2026. link 38 Fukaguchi K, Shinozaki T, Narita ZC, Goto A. Effect of early healthcare visits on cardiovascular disease risk in people with newly screened diabetes: emulating a target trial using a large insurance database. Diabetes research and clinical practice 2026. link 39 Aldafas R, Vinogradova Y, Crabtree TSJ, Gordon J, Idris I. The long-term impact of early HbA1c control on nephropathy, neuropathy, and retinopathy in type 2 diabetes: Findings from a large UK observational study. Journal of diabetes and its complications 2026. link 40 Martín-Saladich Q, Ciudin A, Palomar A, Gámez-Cenzano C, Simó R, González Ballester MA et al.. Disentangling metabolic impairment in the liver-heart axis: tissue-specific insulin sensitivity in type 2 diabetes. Frontiers in endocrinology 2026. link 41 Li YZ, Zhang YT, Li XH. Functions of exosomal microRNAs from adipose tissue in diabetes mellitus and related cardiovascular pathologies. Cell cycle (Georgetown, Tex.) 2026. link 42 Yan C, Hu S, Cao G, Ma G. A bibliometric analysis of myocardial fibrosis in diabetic cardiomyopathy: global trends and future directions. Journal of cardiothoracic surgery 2026. link 43 Lu ES, Cui Y, Phu KK, Ding X, Nodecker KN, Le R et al.. Expanded Field Optical Coherence Tomography Angiography Biomarkers Associated with Future Cardiovascular Disease and Mortality in Patients with Diabetic Retinopathy. Retina (Philadelphia, Pa.) 2026. link 44 Baier JM, Funck KL, Vernstrøm L, Gullaksen S, Laugesen E, Poulsen PL. Colchicine mitigates arterial stiffness in high-risk patients with type 2 diabetes: a randomized placebo-controlled trial. European journal of preventive cardiology 2026. link 45 Begum NJ, Qasim M, Haq IU, Naveed H, Khan FA, Khan ZU et al.. Integrative Molecular and Structural Profiling of Escherichia coli Virulence Genes in Diabetes-Associated Infections. Current microbiology 2026. link 46 Fitzpatrick R, Wilson JJ, Davison G, McMahon G, Bleakley C, McClean C. Optimising exercise time-of-day for cardiometabolic health: Insights from a systematic review and meta-analysis in varied adult cohorts. Journal of sports sciences 2026. link 47 Chen JW, Yu FT, Chen HA, Huang TF, Chen HS, Wu TE. Glucagon-like peptide-1 receptor agonists and the risk of nonarteritic anterior ischemic optic neuropathy: Evidence from a global real-world cohort. Diabetes & metabolism 2026. link 48 Kirwan M, Henson C, Bancroft-Duroux B, Colegate K, Taylor C, Meharg D et al.. Operationalizing Co-Design in Exercise Interventions with Indigenous Peoples in Australia: Development and Cultural Adaptation of the PrIDE Tools. International journal of environmental research and public health 2026. link 49 Ziori M, Tentolouris A, Eleftheriadou I, Voudouri A, Simati S, Aissopou E et al.. Corneal confocal microscopy and cardiac autonomic neuropathy in individuals with type 1 diabetes mellitus. Journal of diabetes and its complications 2026. link 50 Deb A, Gomez V, Cheng Y, Li Z, Yang J, Dowllah I et al.. Ablation of mitochondrial calcium uniporter alleviates cardiac dysfunction in type 1 diabetes. Cell calcium 2026. link 51 Cai L, Wan H, Sun Y, Middeldorp ME, Zhang Y, Qi L et al.. Atrial fibrillation: an underappreciated complication of diabetes. European heart journal 2026. link 52 Xie J, Zhu Q, Liu X, Qu Y, Jiang Y, Wei J et al.. Association of metabolic dysfunction-associated fatty liver disease with microvascular complications in adults with prediabetes. Nutrition, metabolism, and cardiovascular diseases : NMCD 2026. link 53 Rosen CJ, Ingelfinger JR. GLP-1 Receptor Agonists. The New England journal of medicine 2026. link 54 Li Y, Wang Z, Ma Y, Yang N. The nonlinear association between Body Roundness Index and left ventricular diastolic dysfunction in type 2 diabetes. Frontiers in endocrinology 2026. link 55 Kim DW, Seong EY, Song SH. Diabetic retinopathy Is associated with histologic severity of diabetic kidney disease and systemic inflammation. Acta diabetologica 2026. link 56 Pan J, He L, Ding J, Shao F, Hao Y, Huang X et al.. Yeast β-glucan accelerates diabetic wound healing via macrophage polarization and anti-inflammatory modulation. Burns : journal of the International Society for Burn Injuries 2026. link 57 Janssen JAMJL. Hypothesis: Nutrient Off-Loading and Ectopic Fat Reduction Reverse Insulin Resistance and Improve Cardiovascular Outcomes in Type 2 Diabetes-A Narrative Review. International journal of molecular sciences 2026. link 58 Mo F, Wu K, Lin Y, Yang Z, Lan C, Tang M et al.. Change of plantar tissue and aponeurosis characteristics in diabetes and its indication for ulcer risk. Journal of biomechanics 2026. link 59 Hajiuni K, Salehi S, Rajabli Z, Azadnajafabad S, Akbarpour S, Asgari S et al.. Prevalence and factors associated with comorbidities in Iranian patients with type 2 diabetes: A national study. PloS one 2026. link 60 Orozco-Beltran D, Seidu S, Quesada JA. Routine HbA1c monitoring and cardiovascular outcomes in diabetes: Evidence from a large Spanish cohort. Primary care diabetes 2026. link 61 Yang M, Zhou D, He L, Ren N, Li Y, Fan S. Association between medication adherence and glycaemic control among patients with type 2 diabetes in Luzhou: a retrospective cohort study (2018-2023). BMJ open 2026. link 62 Llauradó G, Cano A, Giménez-Palop O, Albert L, Pareja R, Fernández-Veledo S et al.. Insulin resistance and abdominal adiposity discriminate early vascular aging (higher vascular risk) in adults with type 1 diabetes without cardiovascular events. Diabetes research and clinical practice 2026. link 63 Toropova AA, Razuvaeva YG, Olennikov DN. Dihydrosamidin: the basic khellactone ester derived from . Natural product research 2026. link 64 Sprinkles JK, Howard AG, Hullings AG, Shetye A, Wilkins JT, Graff M et al.. Plasma lipidomics and 15-year risk of incident diabetes: a coronary artery risk development in young adults study. Journal of lipid research 2026. link 65 Stimson RH, Crane MS, Dover AR, Forbes S, Wright RJ, Lyall MJ et al.. CGM-derived average glucose is more strongly associated with microvascular complications than HbA1c in type 1 diabetes. Diabetes, obesity & metabolism 2026. link 66 Sun F, Zhang M, Pan Q, Shen P, Sun Y, Lin H et al.. The association between glycaemic control, normal weight and long-term macrovascular outcomes in people with type 2 diabetes in China: A retrospective study. Diabetes, obesity & metabolism 2026. link 67 Hassan N, Mohamed M, Hassan NA, Mohammed HO, Abdelmoniem HO, Al-Zayat KA et al.. Delonix regia flower extract protects against diabetic cardiac remodeling via modulating eNOS/NO/cGMP and NF-κB/iNOS/TNF-α trajectories. The Journal of pharmacy and pharmacology 2026. link 68 Li HY, Chan TK, Co Shih K, Cheung BMY, Yiu KH, Tse HF et al.. GLP-1 Receptor Agonists and Risk of Optic Nerve or Vision-Threatening Events in Patients With Type 2 Diabetes or Cardiometabolic Diseases: A Meta-analysis of Randomized Controlled Trials. Diabetes care 2026. link 69 Gebretsadik GG, Yang B, Glenn AJ, Yang AM, Li J, Chan VW et al.. Dietary manganese, type 2 diabetes, and cardiovascular disease: A UK Biobank cohort study and meta-analysis of over 270,000 individuals. The journal of nutrition, health & aging 2026. link 70 Sebastian SA, Padda I, Bimal T, Varma S, Collins J, Ahmad Z et al.. Patient-accessible continuous glucose monitoring for cardiometabolic risk reduction in type 2 diabetes: A meta-analysis of randomized controlled trials. Disease-a-month : DM 2026. link 71 Su R, Zhou X, Steffen LM, Chen C. Identifying the Ratio of Circulating Cinnamoylglycine to Isoleucine as a Biomarker Linking Diet Quality, Microbial Metabolism, and Type 2 Diabetes Risk in the Coronary Artery Risk Development in Young Adults (CARDIA) Cohorts. The Journal of nutrition 2026. link 72 Cornelio CK, Cowart K, Perkins J, Alomar ME, Gayoso RP, Miranda AC et al.. Real-World Cardiovascular Outcomes of GLP-1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer. Pharmacotherapy 2026. link 73 Furundaoturan O, Değirmenci C, Afrashi F, Akkin C, Menteş J, Nalçacı S. The effect of diabetes mellitus to retinal vascularity in patients without diabetic retinopathy. Clinical & experimental optometry 2026. link 74 Giustina A, di Filippo L, Aleksova A, Bollerslev J, Colao AM, Dawson-Hughes B et al.. Consensus statement on vitamin D role in metabolic health. Metabolism: clinical and experimental 2026. link 75 Nanji K, Zaman M, Tai F, Yu CW, Mikhail D, Jomy J et al.. The prevalence of diabetic retinopathy in Indigenous and non-Indigenous populations in Canada: systematic review and meta-analysis. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2026. link 76 Dubský M, Sojáková D, Fejfarová V, Jude EB. Diabetic Peripheral Neuropathy: New Diagnostics and Treatment Perspectives. Drugs & aging 2026. link 77 Ntelis S, Singh LG, Hernandez R, Spanakis EK. A review of the effect of SGLT2 inhibitors on clinical and glycemic outcomes in hospitalized patients: data from studies that included patients with diabetes. Hormones (Athens, Greece) 2026. link 78 Hanlon M, McGuire BE, MacGilchrist C, Kirwan E, Neachtain DN, Dhatariya K et al.. Beyond the wound: A scoping review of the psychosocial impact of diabetes-related foot ulcers. Diabetic medicine : a journal of the British Diabetic Association 2026. link 79 Zheng Z, Song Y, Cui K, He J, Bian X, Song C et al.. Prognostic stratification of cardiovascular risk and cardiac remodeling in prediabetes: a multimodal analysis comparing ADA and WHO/IEC diagnostic criteria. Cardiovascular diabetology 2026. link 80 O'Meara R, Quigley T, Gorantla A, Helenowski I, Halandras P. Lower Extremity Amputation in the Unhoused Population. Annals of vascular surgery 2026. link 81 Willis K, Shakespeare R, Chandrasekaran L, Chaudhry U, Wahlich C, Chambers R et al.. What are the perceptions and concerns of people living with diabetes and National Health Service staff around the potential implementation of AI-assisted screening for diabetic eye disease?. Diabetic medicine : a journal of the British Diabetic Association 2026. link 82 Moon JH, Jung HN, Kim B, Ko SH, Kwak SH, Han KD et al.. Diabetes in Pregnancy in Korea: Prevalence, Clinical Characteristics, and Postpartum Comorbidities. Diabetes & metabolism journal 2026. link 83 Darji D, Wamelink KE, Minc SD, Farber F, Brennan MB, Tan TW et al.. Benefits of Multi-Disciplinary Limb Preservation Teams. Clinics in podiatric medicine and surgery 2026. link 84 Gao H, Yi Y. Association of Monocyte to Lymphocyte, Neutrophil to Lymphocyte, and Platelet to Lymphocyte Ratios With Non-Healing Lower Extremity Ulcers in Patients With Type 2 Diabetes. The international journal of lower extremity wounds 2026. link 85 Yu Z. Comparison of best corrected visual acuity estimates between a custom-made digital chart and the ETDRS chart. Upsala journal of medical sciences 2026. link 86 Mathew HA, Jayashankar CA, Srinivasan S, Mathew HR, Bhat N, Manish GR et al.. Prevalence of Left Ventricular Diastolic Dysfunction in Normotensive Patients with Type 2 Diabetes Mellitus. Annals of African medicine 2026. link 87 Hou N, Jiao Y, Zhang R, Liu A, Lou H, Zhu Y et al.. Impact of fetal and maternal genetically predicted birth weight on cardiometabolic risk: a Mendelian randomization study of cytokine mediation in Europeans. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2026. link 88 Baribeau V, Ponukumati AS, Krafcik BM, Newton LE, Goodney PP. Scoping Review of Risk Factors for Lower Extremity Amputation in Patients with Concomitant Diabetes Mellitus and Peripheral Arterial Disease. Annals of vascular surgery 2026. link 89 Xiang Y, Tang X, Xiao Y, Li X, Huang G, Zhou Q et al.. Treatment-related progression of subclinical atherosclerosis in latent autoimmune diabetes in adults: A two-year longitudinal study. Journal of diabetes and its complications 2026. link 90 Gomes JAF, Nascimento RLD, de Brito Gomes JL. Blood pressure responses after different interval configurations in aerobic exercise: a systematic review in adolescents and adults with type-1 diabetes. Journal of bodywork and movement therapies 2026. link 91 Bubun J, Yusuf S, Syam Y, Hidayat W, Majid S. Validity and Reliability Diabetic Foot Check-up as a Simple Screening Test of Diabetic Foot Ulcers in a Community. The international journal of lower extremity wounds 2026. link 92 Shokravi A, Seth J, Mancini GBJ. Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis. Cardiovascular diabetology 2026. link 93 Ulrich FS, Napoli N, Nielsen MF, Burden AM. Real-world persistence and dose titration of GLP-1 receptor agonists in type 2 diabetes: A UK population-based cohort study by obesity and cardiovascular disease status. Diabetes, obesity & metabolism 2026. link 94 Vazquez Arreola E, Gong Q, Hanson RL, Wang J, Sandforth L, He S et al.. Prediabetes remission and cardiovascular morbidity and mortality: post-hoc analyses from the Diabetes Prevention Program Outcome study and the DaQing Diabetes Prevention Outcome study. The lancet. Diabetes & endocrinology 2026. link00295-5) 95 Maier GA, Hennig B, Rathmann W, Kuss O. Comparative effectiveness of combination therapy with SGLT-2 inhibitors and GLP-1 RAs compared with SGLT-2 inhibitors in individuals with type 2 diabetes: A prevalent new-user cohort study. Diabetes, obesity & metabolism 2026. link 96 Yin H, Ma Y, Liu X, Liu C, Dong T, Kong L et al.. Diabetes-related foot disease and sarcopenia-related traits: evidence from US and Chinese cohorts and mendelian randomization. Aging clinical and experimental research 2026. link 97 Cho SH, Kim S, Oh R, Kim JY, Jang M, Lee YB et al.. High incidence of eating disorders in individuals with type 2 diabetes and their association with cardiovascular and mortality risks. Diabetologia 2026. link 98 Wu CY, Sharma A, Edwards JD, Liu PP, Kapral MK, Herrmann N et al.. Cardiovascular effectiveness and safety of SGLT2 inhibitors vs DPP4 inhibitors by dementia status: a cohort study of older adults with diabetes. Diabetologia 2026. link 99 Karapınar Göze E, Ürün Ünal B, Ünlü A, Açılan İ. Beyond glycemia: adropin, asprosin, and irisin as potential biomarkers for cardiovascular risk in diabetes and prediabetes. Scientific reports 2026. link 100 Mori T, Kuß O, Mader JK, Naudorf M, Seufert J, Holl RW et al.. GLP-1 receptor agonists or SGLT2-inhibitors? Evaluation of a personalized treatment algorithm for individuals with type 2 diabetes: a registry-based cohort study. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2026. link

Original source

[1]
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes care (2026)
[2]
Barriers and facilitators to the use of tele-ophthalmology in diabetic eye care: a scoping review. — Nopour R BMC health services research (2026)
[3]
Systematic review of ocular and circulatory cytokines linking diabetic retinopathy to kidney disease. — Tang Y, Li Z, Jia Z Frontiers in endocrinology (2026)
[4]
AI-led intervention may be viable option for diabetes prevention. — Rosenberg K The American journal of nursing (2026)
[5]
Assessing the Complexity of Inpatient Care Managed by Endocrinologists in a Tertiary Care Teaching Hospital. — Cook CB, Thompson BM, Perrin AJ, Castro JC, McGary AK, Buras MR Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2026)
[6]
Efficacy of ChatGPT in personalized glucose-lowering strategy development: a clinician-based comparative study. — Wang Y, Zhang CL, Zhao H, Wang C, Guo L, Wei P et al. Frontiers in endocrinology (2026)
[7]
Trends in admissions for hyperglycaemic emergencies and associated clinical factors in adults with type 2 diabetes in Singapore, 2013-2022. — Sng GGR, Lim GH, Tian KJY, Bee YM, Teh MM Diabetic medicine : a journal of the British Diabetic Association (2026)
[8]
Associations Between Comorbidities, Medication Use and Dental Outcomes in Clinical Practice in Hail Dental Centre in Saudi Arabia: A Retrospective Study. — Alotaibi AO, Bakitian F, Alshammari HD, Alqhtani A, Elboraey MO, Fayad MI et al. Oral health & preventive dentistry (2026)
[9]
Experienced stigma in Japanese outpatients with diabetes: Age and polypharmacy matter. — Kubo H, Sozu T, Mitsunaga R, Hazama H, Sekikawa N, Wada R et al. Medicine (2026)
[10]
The Prevalence and Implications of Polypharmacy in Individuals With Type 1 Diabetes. — Ali N, van Erp S, Kramers C, Tack CJ, de Galan BE Clinical pharmacology and therapeutics (2026)
[11]
Polypharmacy and potentially inappropriate prescribing in people with type 2 diabetes: An analysis of the Scottish Diabetes Research Network national diabetes cohort. — Berthon W, McGurnaghan SJ, Blackbourn LAK, Fernandes AAS, Walker LE, McCrimmon RJ et al. Diabetic medicine : a journal of the British Diabetic Association (2026)
[12]
Medication Use in Type 1 Diabetes and the Association with Socioeconomic Disadvantage: Analysis of a National Linked Dataset. — Zomer E, Morton JI, Chen L, Talic S, McAuley SA, Davis EA et al. Diabetes technology & therapeutics (2026)
[13]
Fulminant type 1 diabetes mellitus: a neglected but high-risk adverse event associated with immune checkpoint inhibitors. — Meng K, Fu S, Huang Y, Chen W, Zou W Expert opinion on drug safety (2026)
[14]
Safety Assessment of Glucagon-Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations. — Li Z, Huang J, Zhou S, Luan Y, Xie H, Chen Z et al. Journal of diabetes research (2026)
[15]
Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System. — Ohyama K, Abe N, Okamoto T, Hori Y International journal of clinical pharmacology and therapeutics (2026)
[16]
Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study. — McIntyre RS, Kwan ATH Expert opinion on drug safety (2026)
[17]
Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS). — Xiong W, Li Y, Huang J, He G, Sun J PloS one (2026)
[18]
Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database. — Murray M, Schifano F, Chiappini S, Corkery JM, Guirguis A American journal of ophthalmology (2026)
[19]
A FAERS database study on visual impairment adverse events associated with three long-acting insulin analogues. — Zhong L, Cao W, Liu X, Wen T, Yan J Frontiers in endocrinology (2026)
[20]
Multi-database pharmacovigilance assessment of GLP-1 receptor agonist-related ophthalmic risks using advanced signal detection in FAERS and vigibase. — Cheng X, Jiang Z, Li G, Wang J, Han F Journal of endocrinological investigation (2026)
[21]
Serious adverse events reported with sodium-glucose cotransporter-2 (SGLT2) inhibitors in the FAERS database (2013-2024): a pharmacovigilance study. — Ahsan M Naunyn-Schmiedeberg's archives of pharmacology (2026)
[22]
Diabetic adverse events associated with three commonly used statins: a disproportionality analysis based on the FDA adverse event reporting system database. — Deng B, Li S, You R, Fu Z Expert opinion on drug safety (2026)
[23]
Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024. — Fat MN, Johnson HC, Farberg AS Journal of drugs in dermatology : JDD (2026)
[24]
Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. — McCall KL, Mastro Dwyer KA, Casey RT, Samana TN, Sulicz EK, Tso SY et al. Expert opinion on drug safety (2026)
[25]
Can artificial intelligence and wearable technologies transform diabetes foot health? — Kong WM, Saif F Current opinion in endocrinology, diabetes, and obesity (2026)
[26]
Invasive coronary physiology assessment and predictors of coronary microvascular dysfunction in patients with diabetes mellitus. — Benedetti A, Bringmans T, Vanhaverbeke M, Mathieu FD, Palmers PJ, Coussement P et al. Microvascular research (2026)
[27]
Doppler sonographic evaluation of peripheral arterial disease and its associated factors among diabetes mellitus patients at Muhimbili National Hospital, Tanzania: A hospital-based cross-sectional study. — Sumawe JA, Salingwa L PloS one (2026)
[28]
VEGFA-centric angiogenic genetic variants drive hypertension and dyslipidaemia susceptibility in type 2 diabetes mellitus: A multilocus synergistic cohort study. — Zuo C, Chen H, Lu X, Cheng J, Yang D, Liu Y et al. Diabetic medicine : a journal of the British Diabetic Association (2026)
[29]
Statin prescribing patterns in cardiovascular risk management among outpatients with type 2 diabetes: Real-world practices at a Vietnamese general hospital. — Bui L, Le TT, Dao NH, Nguyen HT, Nguyen TT, Pham VTT et al. PloS one (2026)
[30]
Optimising lipid monitoring interval for primary prevention of cardiovascular disease in patients with type-2 diabetes: A target trial emulation study. — Wang B, Tse ETY, Chui CSL, Lam CLK, Wan EYF Diabetes research and clinical practice (2026)
[31]
Age- and diet-dependent progression of retinal microvascular injury in GCK-MODY under metabolic stress. — Huang Y, Liu Y, Wang Y, Liu X, Ji S, Chen S et al. Frontiers in endocrinology (2026)
[32]
Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin. — Iwasaki Y, Shimada T, Kishimori T, Kato T, Koike J, Matsumoto T et al. Diabetes research and clinical practice (2026)
[33]
Attenuation of Vascular Dementia Associated Neuroinflammation by Inhibition of the JNK Pathway in HFD/STZ-Induced Diabetic Rat Model. — Firdoos S, Dai R, Shah FA, Younas Z Clinical and experimental pharmacology & physiology (2026)
[34]
Management of the acute diabetic foot : an update. — Chen P, Ahluwalia R, Chuo CB, Johnson-Lynn SE The bone & joint journal (2026)
[35]
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology. — Frampton R, Hocking S, Snaith JR, Greenfield JR Trends in endocrinology and metabolism: TEM (2026)
[36]
Association of routine clinical indicators for metabolic and cardiovascular health with weight loss in non-obese older adults: A case-control study using annual health screening data in Japan. — Tsukatani T, Nakada A Geriatric nursing (New York, N.Y.) (2026)
[37]
Drug-gene interactions and the risk of diabetic microvascular complications: A population-based cohort study. — Li N, Sun J, Li H, Li C, Wang X, Ji J et al. Diabetes, obesity & metabolism (2026)
[38]
Effect of early healthcare visits on cardiovascular disease risk in people with newly screened diabetes: emulating a target trial using a large insurance database. — Fukaguchi K, Shinozaki T, Narita ZC, Goto A Diabetes research and clinical practice (2026)
[39]
The long-term impact of early HbA1c control on nephropathy, neuropathy, and retinopathy in type 2 diabetes: Findings from a large UK observational study. — Aldafas R, Vinogradova Y, Crabtree TSJ, Gordon J, Idris I Journal of diabetes and its complications (2026)
[40]
Disentangling metabolic impairment in the liver-heart axis: tissue-specific insulin sensitivity in type 2 diabetes. — Martín-Saladich Q, Ciudin A, Palomar A, Gámez-Cenzano C, Simó R, González Ballester MA et al. Frontiers in endocrinology (2026)
[41]
Functions of exosomal microRNAs from adipose tissue in diabetes mellitus and related cardiovascular pathologies. — Li YZ, Zhang YT, Li XH Cell cycle (Georgetown, Tex.) (2026)
[42]
A bibliometric analysis of myocardial fibrosis in diabetic cardiomyopathy: global trends and future directions. — Yan C, Hu S, Cao G, Ma G Journal of cardiothoracic surgery (2026)
[43]
Expanded Field Optical Coherence Tomography Angiography Biomarkers Associated with Future Cardiovascular Disease and Mortality in Patients with Diabetic Retinopathy. — Lu ES, Cui Y, Phu KK, Ding X, Nodecker KN, Le R et al. Retina (Philadelphia, Pa.) (2026)
[44]
Colchicine mitigates arterial stiffness in high-risk patients with type 2 diabetes: a randomized placebo-controlled trial. — Baier JM, Funck KL, Vernstrøm L, Gullaksen S, Laugesen E, Poulsen PL European journal of preventive cardiology (2026)
[45]
Integrative Molecular and Structural Profiling of Escherichia coli Virulence Genes in Diabetes-Associated Infections. — Begum NJ, Qasim M, Haq IU, Naveed H, Khan FA, Khan ZU et al. Current microbiology (2026)
[46]
Optimising exercise time-of-day for cardiometabolic health: Insights from a systematic review and meta-analysis in varied adult cohorts. — Fitzpatrick R, Wilson JJ, Davison G, McMahon G, Bleakley C, McClean C Journal of sports sciences (2026)
[47]
Glucagon-like peptide-1 receptor agonists and the risk of nonarteritic anterior ischemic optic neuropathy: Evidence from a global real-world cohort. — Chen JW, Yu FT, Chen HA, Huang TF, Chen HS, Wu TE Diabetes & metabolism (2026)
[48]
Operationalizing Co-Design in Exercise Interventions with Indigenous Peoples in Australia: Development and Cultural Adaptation of the PrIDE Tools. — Kirwan M, Henson C, Bancroft-Duroux B, Colegate K, Taylor C, Meharg D et al. International journal of environmental research and public health (2026)
[49]
Corneal confocal microscopy and cardiac autonomic neuropathy in individuals with type 1 diabetes mellitus. — Ziori M, Tentolouris A, Eleftheriadou I, Voudouri A, Simati S, Aissopou E et al. Journal of diabetes and its complications (2026)
[50]
Ablation of mitochondrial calcium uniporter alleviates cardiac dysfunction in type 1 diabetes. — Deb A, Gomez V, Cheng Y, Li Z, Yang J, Dowllah I et al. Cell calcium (2026)
[51]
Atrial fibrillation: an underappreciated complication of diabetes. — Cai L, Wan H, Sun Y, Middeldorp ME, Zhang Y, Qi L et al. European heart journal (2026)
[52]
Association of metabolic dysfunction-associated fatty liver disease with microvascular complications in adults with prediabetes. — Xie J, Zhu Q, Liu X, Qu Y, Jiang Y, Wei J et al. Nutrition, metabolism, and cardiovascular diseases : NMCD (2026)
[53]
GLP-1 Receptor Agonists. — Rosen CJ, Ingelfinger JR The New England journal of medicine (2026)
[54]
The nonlinear association between Body Roundness Index and left ventricular diastolic dysfunction in type 2 diabetes. — Li Y, Wang Z, Ma Y, Yang N Frontiers in endocrinology (2026)
[55]
Diabetic retinopathy Is associated with histologic severity of diabetic kidney disease and systemic inflammation. — Kim DW, Seong EY, Song SH Acta diabetologica (2026)
[56]
Yeast β-glucan accelerates diabetic wound healing via macrophage polarization and anti-inflammatory modulation. — Pan J, He L, Ding J, Shao F, Hao Y, Huang X et al. Burns : journal of the International Society for Burn Injuries (2026)
[57]
Hypothesis: Nutrient Off-Loading and Ectopic Fat Reduction Reverse Insulin Resistance and Improve Cardiovascular Outcomes in Type 2 Diabetes-A Narrative Review. — Janssen JAMJL International journal of molecular sciences (2026)
[58]
Change of plantar tissue and aponeurosis characteristics in diabetes and its indication for ulcer risk. — Mo F, Wu K, Lin Y, Yang Z, Lan C, Tang M et al. Journal of biomechanics (2026)
[59]
Prevalence and factors associated with comorbidities in Iranian patients with type 2 diabetes: A national study. — Hajiuni K, Salehi S, Rajabli Z, Azadnajafabad S, Akbarpour S, Asgari S et al. PloS one (2026)
[60]
Routine HbA1c monitoring and cardiovascular outcomes in diabetes: Evidence from a large Spanish cohort. — Orozco-Beltran D, Seidu S, Quesada JA Primary care diabetes (2026)
[61]
Association between medication adherence and glycaemic control among patients with type 2 diabetes in Luzhou: a retrospective cohort study (2018-2023). — Yang M, Zhou D, He L, Ren N, Li Y, Fan S BMJ open (2026)
[62]
Insulin resistance and abdominal adiposity discriminate early vascular aging (higher vascular risk) in adults with type 1 diabetes without cardiovascular events. — Llauradó G, Cano A, Giménez-Palop O, Albert L, Pareja R, Fernández-Veledo S et al. Diabetes research and clinical practice (2026)
[63]
Dihydrosamidin: the basic khellactone ester derived from — Toropova AA, Razuvaeva YG, Olennikov DN Natural product research (2026)
[64]
Plasma lipidomics and 15-year risk of incident diabetes: a coronary artery risk development in young adults study. — Sprinkles JK, Howard AG, Hullings AG, Shetye A, Wilkins JT, Graff M et al. Journal of lipid research (2026)
[65]
CGM-derived average glucose is more strongly associated with microvascular complications than HbA1c in type 1 diabetes. — Stimson RH, Crane MS, Dover AR, Forbes S, Wright RJ, Lyall MJ et al. Diabetes, obesity & metabolism (2026)
[66]
The association between glycaemic control, normal weight and long-term macrovascular outcomes in people with type 2 diabetes in China: A retrospective study. — Sun F, Zhang M, Pan Q, Shen P, Sun Y, Lin H et al. Diabetes, obesity & metabolism (2026)
[67]
Delonix regia flower extract protects against diabetic cardiac remodeling via modulating eNOS/NO/cGMP and NF-κB/iNOS/TNF-α trajectories. — Hassan N, Mohamed M, Hassan NA, Mohammed HO, Abdelmoniem HO, Al-Zayat KA et al. The Journal of pharmacy and pharmacology (2026)
[68]
GLP-1 Receptor Agonists and Risk of Optic Nerve or Vision-Threatening Events in Patients With Type 2 Diabetes or Cardiometabolic Diseases: A Meta-analysis of Randomized Controlled Trials. — Li HY, Chan TK, Co Shih K, Cheung BMY, Yiu KH, Tse HF et al. Diabetes care (2026)
[69]
Dietary manganese, type 2 diabetes, and cardiovascular disease: A UK Biobank cohort study and meta-analysis of over 270,000 individuals. — Gebretsadik GG, Yang B, Glenn AJ, Yang AM, Li J, Chan VW et al. The journal of nutrition, health & aging (2026)
[70]
Patient-accessible continuous glucose monitoring for cardiometabolic risk reduction in type 2 diabetes: A meta-analysis of randomized controlled trials. — Sebastian SA, Padda I, Bimal T, Varma S, Collins J, Ahmad Z et al. Disease-a-month : DM (2026)
[71]
Identifying the Ratio of Circulating Cinnamoylglycine to Isoleucine as a Biomarker Linking Diet Quality, Microbial Metabolism, and Type 2 Diabetes Risk in the Coronary Artery Risk Development in Young Adults (CARDIA) Cohorts. — Su R, Zhou X, Steffen LM, Chen C The Journal of nutrition (2026)
[72]
Real-World Cardiovascular Outcomes of GLP-1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer. — Cornelio CK, Cowart K, Perkins J, Alomar ME, Gayoso RP, Miranda AC et al. Pharmacotherapy (2026)
[73]
The effect of diabetes mellitus to retinal vascularity in patients without diabetic retinopathy. — Furundaoturan O, Değirmenci C, Afrashi F, Akkin C, Menteş J, Nalçacı S Clinical & experimental optometry (2026)
[74]
Consensus statement on vitamin D role in metabolic health. — Giustina A, di Filippo L, Aleksova A, Bollerslev J, Colao AM, Dawson-Hughes B et al. Metabolism: clinical and experimental (2026)
[75]
The prevalence of diabetic retinopathy in Indigenous and non-Indigenous populations in Canada: systematic review and meta-analysis. — Nanji K, Zaman M, Tai F, Yu CW, Mikhail D, Jomy J et al. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie (2026)
[76]
Diabetic Peripheral Neuropathy: New Diagnostics and Treatment Perspectives. — Dubský M, Sojáková D, Fejfarová V, Jude EB Drugs & aging (2026)
[77]
A review of the effect of SGLT2 inhibitors on clinical and glycemic outcomes in hospitalized patients: data from studies that included patients with diabetes. — Ntelis S, Singh LG, Hernandez R, Spanakis EK Hormones (Athens, Greece) (2026)
[78]
Beyond the wound: A scoping review of the psychosocial impact of diabetes-related foot ulcers. — Hanlon M, McGuire BE, MacGilchrist C, Kirwan E, Neachtain DN, Dhatariya K et al. Diabetic medicine : a journal of the British Diabetic Association (2026)
[79]
Prognostic stratification of cardiovascular risk and cardiac remodeling in prediabetes: a multimodal analysis comparing ADA and WHO/IEC diagnostic criteria. — Zheng Z, Song Y, Cui K, He J, Bian X, Song C et al. Cardiovascular diabetology (2026)
[80]
Lower Extremity Amputation in the Unhoused Population. — O'Meara R, Quigley T, Gorantla A, Helenowski I, Halandras P Annals of vascular surgery (2026)
[81]
What are the perceptions and concerns of people living with diabetes and National Health Service staff around the potential implementation of AI-assisted screening for diabetic eye disease? — Willis K, Shakespeare R, Chandrasekaran L, Chaudhry U, Wahlich C, Chambers R et al. Diabetic medicine : a journal of the British Diabetic Association (2026)
[82]
Diabetes in Pregnancy in Korea: Prevalence, Clinical Characteristics, and Postpartum Comorbidities. — Moon JH, Jung HN, Kim B, Ko SH, Kwak SH, Han KD et al. Diabetes & metabolism journal (2026)
[83]
Benefits of Multi-Disciplinary Limb Preservation Teams. — Darji D, Wamelink KE, Minc SD, Farber F, Brennan MB, Tan TW et al. Clinics in podiatric medicine and surgery (2026)
[84]
Association of Monocyte to Lymphocyte, Neutrophil to Lymphocyte, and Platelet to Lymphocyte Ratios With Non-Healing Lower Extremity Ulcers in Patients With Type 2 Diabetes. — Gao H, Yi Y The international journal of lower extremity wounds (2026)
[85]
Comparison of best corrected visual acuity estimates between a custom-made digital chart and the ETDRS chart. — Yu Z Upsala journal of medical sciences (2026)
[86]
Prevalence of Left Ventricular Diastolic Dysfunction in Normotensive Patients with Type 2 Diabetes Mellitus. — Mathew HA, Jayashankar CA, Srinivasan S, Mathew HR, Bhat N, Manish GR et al. Annals of African medicine (2026)
[87]
Impact of fetal and maternal genetically predicted birth weight on cardiometabolic risk: a Mendelian randomization study of cytokine mediation in Europeans. — Hou N, Jiao Y, Zhang R, Liu A, Lou H, Zhu Y et al. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2026)
[88]
Scoping Review of Risk Factors for Lower Extremity Amputation in Patients with Concomitant Diabetes Mellitus and Peripheral Arterial Disease. — Baribeau V, Ponukumati AS, Krafcik BM, Newton LE, Goodney PP Annals of vascular surgery (2026)
[89]
Treatment-related progression of subclinical atherosclerosis in latent autoimmune diabetes in adults: A two-year longitudinal study. — Xiang Y, Tang X, Xiao Y, Li X, Huang G, Zhou Q et al. Journal of diabetes and its complications (2026)
[90]
Blood pressure responses after different interval configurations in aerobic exercise: a systematic review in adolescents and adults with type-1 diabetes. — Gomes JAF, Nascimento RLD, de Brito Gomes JL Journal of bodywork and movement therapies (2026)
[91]
Validity and Reliability Diabetic Foot Check-up as a Simple Screening Test of Diabetic Foot Ulcers in a Community. — Bubun J, Yusuf S, Syam Y, Hidayat W, Majid S The international journal of lower extremity wounds (2026)
[92]
Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis. — Shokravi A, Seth J, Mancini GBJ Cardiovascular diabetology (2026)
[93]
Real-world persistence and dose titration of GLP-1 receptor agonists in type 2 diabetes: A UK population-based cohort study by obesity and cardiovascular disease status. — Ulrich FS, Napoli N, Nielsen MF, Burden AM Diabetes, obesity & metabolism (2026)
[94]
Prediabetes remission and cardiovascular morbidity and mortality: post-hoc analyses from the Diabetes Prevention Program Outcome study and the DaQing Diabetes Prevention Outcome study. — Vazquez Arreola E, Gong Q, Hanson RL, Wang J, Sandforth L, He S et al. The lancet. Diabetes & endocrinology (2026)
[95]
Comparative effectiveness of combination therapy with SGLT-2 inhibitors and GLP-1 RAs compared with SGLT-2 inhibitors in individuals with type 2 diabetes: A prevalent new-user cohort study. — Maier GA, Hennig B, Rathmann W, Kuss O Diabetes, obesity & metabolism (2026)
[96]
Diabetes-related foot disease and sarcopenia-related traits: evidence from US and Chinese cohorts and mendelian randomization. — Yin H, Ma Y, Liu X, Liu C, Dong T, Kong L et al. Aging clinical and experimental research (2026)
[97]
High incidence of eating disorders in individuals with type 2 diabetes and their association with cardiovascular and mortality risks. — Cho SH, Kim S, Oh R, Kim JY, Jang M, Lee YB et al. Diabetologia (2026)
[98]
Cardiovascular effectiveness and safety of SGLT2 inhibitors vs DPP4 inhibitors by dementia status: a cohort study of older adults with diabetes. — Wu CY, Sharma A, Edwards JD, Liu PP, Kapral MK, Herrmann N et al. Diabetologia (2026)
[99]
Beyond glycemia: adropin, asprosin, and irisin as potential biomarkers for cardiovascular risk in diabetes and prediabetes. — Karapınar Göze E, Ürün Ünal B, Ünlü A, Açılan İ Scientific reports (2026)
[100]
GLP-1 receptor agonists or SGLT2-inhibitors? Evaluation of a personalized treatment algorithm for individuals with type 2 diabetes: a registry-based cohort study. — Mori T, Kuß O, Mader JK, Naudorf M, Seufert J, Holl RW et al. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association (2026)

Share:Twitter Reddit LinkedIn